Recombinant Human Melanoma-associated antigen 4 (MAGEA4) (Active)

In Stock
Code CSB-MP013330HU
MSDS
Size $318
Order now
Image
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
  • Activity
    Measured by its binding ability in a functional ELISA. Immobilized Human MAGEA4 at 2 μg/ml can bind anti-MAGEA4 recombinant antibody, the EC50 is 30.33-43.10 ng/mL. Biological Activity Assay
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
Greater than 90% as determined by SDS-PAGE.
Endotoxin
Less than 1.0 EU/ug as determined by LAL method.
Activity
Measured by its binding ability in a functional ELISA. Immobilized Human MAGEA4 at 2 μg/Ml can bind anti-MAGEA4 recombinant antibody, the EC50 is 30.33-43.10 ng/mL.
Target Names
MAGEA4
Uniprot No.
Alternative Names
(Cancer/testis antigen 1.4) (CT1.4) (MAGE-4 antigen) (MAGE-41 antigen) (MAGE-X2 antigen)
Molecular Characterization
Species
Homo sapiens (Human)
Source
Mammalian cell
Expression Region
1-317aa
Target Protein Sequence
MSSEQKSQHCKPEEGVEAQEEALGLVGAQAPTTEEQEAAVSSSSPLVPGTLEEVPAAESAGPPQSPQGASALPTTISFTCWRQPNEGSSSQEEEGPSTSPDAESLFREALSNKVDELAHFLLRKYRAKELVTKAEMLERVIKNYKRCFPVIFGKASESLKMIFGIDVKEVDPASNTYTLVTCLGLSYDGLLGNNQIFPKTGLLIIVLGTIAMEGDSASEEEIWEELGVMGVYDGREHTVYGEPRKLLTQDWVQENYLEYRQVPGSNPARYEFLWGPRALAETSYVKVLEHVVRVNARVRIAYPSLREAALLEEEEGV
Mol. Weight
36.7 kDa
Protein Length
Full Length
Tag Info
C-terminal 10xHis-tagged
Form
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer
Lyophilized from a 0.2 μm filtered 20 mM Tris-HCl, 0.5 M NaCl, 6% Trehalose, pH 8.0
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
Basically, we can dispatch the products out in 3-7 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.
Description

The Recombinant Human MAGEA4 is a full-length melanoma-associated antigen 4 protein, which spans the 1-317aa expression region. Produced in mammalian cells, this protein is essential for cancer research. With a C-terminal 10xHis-tag, MAGEA4 displays a purity greater than 90% as confirmed by SDS-PAGE analysis. The endotoxin levels are kept under 1.0 EU/µg, as determined through the LAL method. The functionality of MAGEA4 is demonstrated in a binding assay, where immobilized MAGEA4 at 2 μg/mL can bind anti-MAGEA4 recombinant antibody with an EC50 range of 30.33-43.10 ng/mL. The product comes in a lyophilized powder form for convenient storage and application in various research projects.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Regulates cell proliferation through the inhibition of cell cycle arrest at the G1 phase. Also negatively regulates p53-mediated apoptosis.
Gene References into Functions
  1. MAGEA4 was positively correlated with TWIST1, and its knockdown inhibited EMT in TE3 cells. PMID: 28653599
  2. Because of the significant correlation of MAGEA4 and indices of poor prognosis, the role of this CTA may be confirmed in Esophageal squamous cell carcinoma (ESCC) aggressiveness and metastasis. Therefore, MAGEA4 may be a promising therapeutic candidate for suppressing ESCC aggressiveness PMID: 30197348
  3. Study shows that whereas MAGEA4 expression by itself may be indicative of a poor prognosis in primary lung cancer, its prognostic value depends entirely on its subcellular localization and on the p53 status. The accumulation of nuclear MAGEA4 expression without p53 expression is significantly associated with poor survival, implying that MAGEA4 inhibits apoptosis and increases tumorigenesis. PMID: 29901069
  4. MAGE-A4 depletion from MAGE-A4-expressing cancer cells destabilizes RAD18. PMID: 27377895
  5. Our results support...the potential utility of MAGEA4 as an ancillary diagnostic marker for synovial sarcoma PMID: 28744588
  6. some autoantibodies, such as anti-MAGEA4, anti-CTAG1 or anti-TP53 and their combinations could possibly contribute to the development of cancer early detection tests (not necessarily restricted to gastric cancer) when being combined with other markers. PMID: 27140836
  7. Anti-MAGEA4 exhibited the highest sensitivity for detecting early stage colorectal cancer (CRC) and advanced adenoma. PMID: 26909861
  8. High MAGE-A4 expression is associated with Lung Cancer. PMID: 27793776
  9. Results found concomitant overexpression of MAGEA4 and TWIST1 in esophageal squamous cell carcinoma (ESCC). Also, it showed a correlation between MAGEA4 and TWIST1 expression, which was found as indirect binding of TWIST1 to the E-boxes in the MAGEA4 promoter revealing transcriptional upregulation of MAGEA4 by TWIST1. PMID: 27533647
  10. Results support the potential utility of NY-ESO-1, PRAME, and MAGEA4 as targets for immunotherapy and as ancillary prognostic parameters in synovial sarcomas. PMID: 27993576
  11. CTAs (MAGE-A4, NY-ESO-1, MAGE-A10) were more likely expressed in patients with squamous cell carcinoma of the lung and when CTAs combined with CD133, they can be better prognostic factors. PMID: 26191258
  12. HLA class I loss in smokers or patients with the MAGE-A4 gene was a prognostic factors in non-small cell lung cancer . PMID: 23124547
  13. Expression of MAGE-A4 may make immunotherapeutic intervention possible in selected patients with thyroid cancer. PMID: 24238058
  14. Detection of MAGE-4 transcripts in blood may help to predict the prognosis and monitoring of the response of HCV-infected hepatocellular carcinoma patients to therapy PMID: 22653756
  15. Mage-A4 expression and serum identification is and potential therapeutic target in estrogen receptor negative breast cancer. PMID: 23172894
  16. MAGEA4 promotes growth by preventing cell cycle arrest and by inhibiting apoptosis mediated by the p53 transcriptional targets. PMID: 22842486
  17. High MAGE-4 gene expression is associated with metastases in hepatitis C virus patients complicated by hepatocellular carcinoma. PMID: 21452042
  18. MAGE-A4 is identified as a specific biomarker of esophageal squamous cell carcinoma with a possible oncogenic role contributing to tumor progression. PMID: 21613820
  19. novel HLA-A2-restricted T cell epitope derived from MAGE-4 was identified PMID: 21815906
  20. High MAGE-A4 gene expression is associated with head and neck squamous cell carcinoma PMID: 20715104
  21. Report immunohistochemical expression of MAGE-A4 in renal oncocytoma and chromophobe renal cell carcinoma. PMID: 20591578
  22. positive expression in patients with non-small cell lung cancer is associated with poorer overall survival PMID: 19545928
  23. MAGE-4 protein may have a role in development of hepatocellular carcinogenesis in cirrhotic patients PMID: 11985796
  24. MAGE-A4 expression in bladder transitional cell carcinoma. PMID: 12209610
  25. strong MAGE-A4 expression and to a lesser degree NY-ESO-1 expression is characteristic of the vast majority of uterine carcinosarcomas and a major subset of papillary serous carcinomas PMID: 12209997
  26. MAGE-A4 binds to gankyrin and suppresses its oncogenic activity. PMID: 12525503
  27. a cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis PMID: 14739298
  28. MAGE-A4(143-151) and SAGE(715-723) are HLA-A2402-restricted CTL epitopes PMID: 16061876
  29. Expression may represent potential targets for cancer immunotherapy in patients with non small cell lung carcinoma. PMID: 16596224
  30. Expressed in a large part of epithelial skin tumors with predominantly scattered immunoexpression pattern in organ-transplant recipients. PMID: 17214847
  31. Its expression is significantly associated with prognostic factors in poor outcome of the non-small cell lung cancer. PMID: 18982744
  32. Overexpression of MAGE-A4 is associated with bladder cancer. PMID: 19533752

Show More

Hide All

Tissue Specificity
Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes and placenta.
Database Links

HGNC: 6802

OMIM: 300175

KEGG: hsa:4103

STRING: 9606.ENSP00000276344

UniGene: Hs.37107

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*